LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Search

Harvard Bioscience Inc

Suletud

SektorTervishoid

0.66 3.13

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.63

Max

0.73

Põhinäitajad

By Trading Economics

Sissetulek

1.1M

-1.2M

Müük

141K

21M

Kasumimarginaal

-5.978

Töötajad

330

EBITDA

42K

197K

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+203.03% upside

Turustatistika

By TradingEconomics

Turukapital

321K

26M

Eelmine avamishind

-2.47

Eelmine sulgemishind

0.66

Uudiste sentiment

By Acuity

50%

50%

185 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

Harvard Bioscience Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. nov 2025, 18:59 UTC

Suurimad hinnamuutused turgudel

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17. nov 2025, 23:40 UTC

Market Talk

Gold Consolidates Amid Mixed Signals -- Market Talk

17. nov 2025, 23:34 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17. nov 2025, 22:58 UTC

Market Talk

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17. nov 2025, 22:46 UTC

Market Talk

Risk Assets Set to Have a Strong 2026 -- Market Talk

17. nov 2025, 22:06 UTC

Omandamised, ülevõtmised, äriostud

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17. nov 2025, 22:02 UTC

Tulu

Trip.com Group 3Q Rev $2.6B >TCOM

17. nov 2025, 22:02 UTC

Tulu

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17. nov 2025, 22:02 UTC

Tulu

Trip.com Group 3Q EPS $4.02 >TCOM

17. nov 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. nov 2025, 21:40 UTC

Tulu

James Hardie Industries 2Q Adj EPS 26c >JHX

17. nov 2025, 21:40 UTC

Tulu

James Hardie Industries 2Q Loss/Shr 10c >JHX

17. nov 2025, 21:39 UTC

Tulu

James Hardie Industries 2Q Sales $1.29B >JHX

17. nov 2025, 21:38 UTC

Tulu
Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17. nov 2025, 21:38 UTC

Tulu

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17. nov 2025, 21:10 UTC

Tulu

XP Inc. 3Q EPS BRL2.47 >XP

17. nov 2025, 21:10 UTC

Tulu

XP Inc. 3Q Rev BRL4.67B >XP

17. nov 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17. nov 2025, 20:12 UTC

Market Talk

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17. nov 2025, 20:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. nov 2025, 20:09 UTC

Market Talk

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17. nov 2025, 19:29 UTC

Market Talk

Gold Slide Continues to Start Week -- Market Talk

17. nov 2025, 19:16 UTC

Tulu
Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17. nov 2025, 18:20 UTC

Omandamised, ülevõtmised, äriostud

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17. nov 2025, 16:45 UTC

Omandamised, ülevõtmised, äriostud

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17. nov 2025, 16:16 UTC

Tulu
Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17. nov 2025, 16:15 UTC

Tulu

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17. nov 2025, 15:40 UTC

Omandamised, ülevõtmised, äriostud

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17. nov 2025, 15:22 UTC

Omandamised, ülevõtmised, äriostud

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17. nov 2025, 15:19 UTC

Market Talk

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Harvard Bioscience Inc Prognoos

Hinnasiht

By TipRanks

203.03% tõus

12 kuu keskmine prognoos

Keskmine 2 USD  203.03%

Kõrge 2 USD

Madal 2 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Harvard Bioscience Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

1

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

0.3 / 0.3401Toetus ja vastupanu

Lühikene perspektiiv

Weak Bearish Evidence

Keskpikk perspektiiv

No Evidence

Pikk perspektiiv

No Evidence

Sentiment

By Acuity

185 / 374 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat